Androgen derivatives for use in the inhibition of sex steroid ac

Details Androgen derivatives for use in the inhibition of sex steroid ac Androgen derivatives for use in the inhibition of sex steroid ac

1994-07-21

2000-08-29

Shah, Mukund J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ortho-hydroxybenzoic acid or derivative doai

514182, 552623, C07J 100, C07J 500, A61K 31565, A61K 3157

Patent

active

061109061

ABSTRACT:
Methods for treating sex steroid-dependent diseases by inhibiting sex steroid activity include administration of novel compounds which include an androgenic nucleus substituted at a ring carbon with at least one substituent specified herein. Such compounds may function by inhibiting sex steroid synthesis (both estrogen and androgen synthesis) and/or by antagonistically blocking androgen receptors.

REFERENCES:
patent: 3001988 (1961-09-01), Nysted
patent: 3300523 (1967-01-01), Brown
patent: 3975413 (1976-08-01), Pierdet et al.
patent: 3995060 (1976-11-01), Neri et al.
patent: 4024248 (1977-05-01), Koning et al.
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4055641 (1977-10-01), Benson et al.
patent: 4100274 (1978-07-01), Dutta et al.
patent: 4118483 (1978-10-01), Konig et al.
patent: 4139638 (1979-02-01), Neri et al.
patent: 4161540 (1979-07-01), Neri et al.
patent: 4191759 (1980-03-01), Johnston et al.
patent: 4235893 (1980-11-01), Brodie
patent: 4329364 (1982-05-01), Neri et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4481190 (1984-11-01), Nestor et al.
patent: 4547493 (1985-10-01), Teutsch et al.
patent: 4634696 (1987-01-01), Teutsch et al.
patent: 4659516 (1987-04-01), Bowler et al.
patent: 4659695 (1987-04-01), Labrie
patent: 4732912 (1988-03-01), Pilgrim et al.
patent: 4751240 (1988-06-01), Bowler et al.
patent: 4760053 (1988-07-01), Labrie
patent: 4760061 (1988-07-01), Edwards et al.
patent: 4904661 (1990-02-01), Pilgrim et al.
patent: 5021414 (1991-06-01), Pilgrim et al.
patent: 5364847 (1994-11-01), Labrie et al.
Salman, et al., .sup.125 I-Ligand For Progesterone Receptor: 17.alpha.-(6'-Iodohex-1'-ynyl)-19-nortestosterone, J Steroid Biochem vol. 33, No. 1, pp 25-31, 1989.
Green, et al., Nature 320: 134, 1986.
Luthy, etal J Steroidal Biochem. 31(5)845-52 1988.
Plante, J. Steroidal Biochem. 31(1)61-64, 1988.
Voight, etal, EMBO 1973 92(4)pp.1216-22.
Green, etal, Nature 320(13) Mar. 1986 pp.134-139.
Lubahn, etal Science, 1988 pp. 327-330.
Lubahn, etal Proc. Natl. Acad Sci. USA 86 9534-9538 Dec. 1989.
Tora, etal, EMBO 8(7) 1981-1986, 1989.
Doorenbos, etal J.Pharm. Sciences 62(4),1973 pp. 638 to 640.
Doorenbos, etal J. Pharm. Sciences 60(18) 1971 pp. 1234-1235.
Mayfeh, etal Steroids 14:3, 1969 pp. 269 to 283.
Doorenbos, etal J. Pharm. Sciences 63(4) 1974 pp. 620 to 622.
Auchus, etal, Biochemistry 1986 257295-7300 Riess.
Schwartz, Organic Synthesis Collective vol. 3.
Cooke--Jr. Tetrahedron Letters 22 pp. 1923-1986, 1973.
Gibson. etal Angew Chem. Int.Ed. 7(1968)No.12, pp 919-930.
Neri, etal J. Steroidal Biochem. 1975(6) pp 815-819.
Chang, etal Biochemistry 1982 27-410 2-4109.
Gyortii, etal J. Steroidal Biochem. 25(3) 355-358, 1986.
Macaulay,etal J. Steroidal Biochem 26(5)535-538 1987.
Grunwell,etal, Steroids 27(6) 1976 pp. 759 to 771.
Chen, etal J.Biol.Chem 250(19), 1975 pp. 7682-7686.
Rauchee, etal J.Org.Chem, 1981 46 3558-3559.
Weiss, etal Angew Chem.Int.Ed. 12(1973)No. 10 p. 841.
Bull,etal Chem Soc. Chem Commun 1986 p. 451-453.
Wang, etal, Can. J. Chem 65, 2727 1987.
Salman,etal J.Steroidal Biochem. 26(3) 383-391, 1987.
Jordan,etal, Endocrinology, 124(4), 1989 pp.1717 to 1726.
R.J. Donnelly, "Continuous Subcutaneous Administration of `Zoladex` (ICI 118,630--An LH-RH Analogue) to Patients with advanced Prostatic Cancer", ICI Pharmaceuticals Division, Macclesfield, U.K.
Beardwell, C.G., Hindley, A.C., Wilkinson, P.M., Todd, I.D., Pibeiro, G.G., Bu'Lock, D. (1983) Trilostane in the treatment of advanced breast cancer. Cancer Chemother. Pharmacol. 10, No. 3, 158-160.
Brooks, J.R., Berman, D., Glitzer, M.S., Gordon, L.R., Primka, R.L., Reynolds, G.F., Rasmusson, G.H. (1982) Effect on a new 5 alpha-reductase inhibitor on size, histologic, characteristics and androgen concentration of a canine prostate. The Prostate, 3, No. 1, 35-44.
Bruchovsky, N., Wilson, J.D. (1968) The converstion of testosterone to 5.alpha.-androstan-17.beta.-01-3-one by rat prostate in vivo and in vitro J. Biol. Chem. 243, No. 8, 2012-2021.
Coy, D.H., Horvath, A., Nekola, M.F., Coy, E.J., Erchegyi, J., Schally, A.V. (1982) Peptide antagonists of LH-RH: large increases in antiovulatory activities produced by basic D-amino acids in he six position. Endocrinology, 110, 1445-1447.
Debruyne, F.M.J. (1988) The case for LHRH agonists. In: Bailliere's Clinical Oncology International Practice and Research, (Furr, B.J.A., Denis, S., eds). Bailliere's Tindall, pp.559-570.
Labrie, F., Dupont, A., Belanger, A. and members of the Laval University Prostate Cancer Program (1984) Dramatic response to a new antihormonal treatment for prostate cancer. 7th International Congress of Endocrinology 1984, p. 98.
Lambert, A., Frost, J., Mitchell, R., Robertson, W.R. (1986) On the assessment of the in vivo biopotency and site(s) of action of drug affecting adrenal steroidogenesis. Ann. Clin. Biochem., 23, 225-229.
Potts, G.O., Creanage, J.E., Handomg, H.R., Schane, H.P. (1978) Triostane, an orally active inhibitor of steroid biosynthesis. Steroids, 32, No. 2, 257-267.
Wilson, J. (1975) Metabolism of testicular androgens. In: Handbook of Physiology: a critical, comprehensive presentation of physiological knowledge and concepts. Section 7, Endocrinology; vol. V, Male reproductive system, (Hamilton, D. Greep, R.O., eds). Washington, DC: American Physiology Society, pp. 491-508.
Robinson, D.T., Earnshaw, R.J., Mitchell, R., Powles, P., Andrews, R.S., Robertson, W.R. (1984) The bioavailability and metabolism of trisostane in normal subjects, a comparative study using high pressure liquid chromatographic and quantitative cytochemical assays. J. Steroid Biochem., 21, No. 5, 601-605.
Habenicht, U.F., Schwarz, K., Neumann, F., El Etreby, M.F. (1987) Induction of estrogen-related hyperplasic changes in the prostate of the cynomolgus monkey (macaca fascicularis) by androstenedione and its antagonization by the aromatase inhibitor 1-methyl-androsta-I,4-diene-3, 17-dione. The Prostate, 11, 313-326.
DeKlerk, D.P., Human, H.J., De Klerk, J.N. (1985) The effect of 5.alpha.-androstane-3.alpha., 17.beta.-diol and 17.beta.-estradiol on the adult and immature chacma baboon prostate. The Prostate, 7, 1-12.
Coy, D.H., Vilchez-Martinez, J.S., Co, E.J., Schally, A.V. (1976) Analogs of luteinizing hormone-releasing hormone with increased biologival activity produced by D-amino acid substitutions in position 6. J.Med. Chem., 19, No. 3, 423-425.
Wenderoth, U.K., George, F.W., Wilson, J.D. (1983) The effect of a 5.alpha.-reductase inhibition on androgen-mediated growth of the dog prostate. Endocrinology, 113, No. 2, 569-573.
McConnell, J.D., Wilson, J.D., George, F.W., Geller, J., Walsh, P.C., Ewing, L. L., Isaacs, J., Stoner, E. (1989) An inhibitor of 5.alpha.-reductase, MK-906, suppresses prostatic dihydrotestosterone in men with begign prostatic hyperplasia. AUA Eighty-fourth Annual Meeting (Dallas, May 7-11). The Journal of Urology, 141, 239A, No. 280.
Stoner, E. (1989) Lecture on the role of 5-alpha-reductase inhibitor in BPH. AUA Today, No. Nov./Dec.
Toomey, R.E., Goode, R.L. Petrow, V., Neubauer, B.L. (1989) An in vivo assay for conversion of testosterone (T) to dihydrotestosterone (DHT) by prostatic steroid 5-alpha-reductase and comparison of two inhibitors. 71st Annual Meeting of the Endocrine Society Meeting (Seattle, Jun. 21-24). No. 1226, p. 329.
Labrie, C. Cusan, L., Plante, M. Lapointe, S., Labrie, F. (1987) Analysis ofthe androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28, No. 4, 379-384.
Simard, J., Labrie, C., Hubert, J.F., Labrie, F. (1988) Modulation by sex steroids and [D-Trp6, des-gly-NH210] luteinizing hormone (LH)-releasing hormone ethylamide of .alpha.-subunit and LH.beta. messenger ribonucleic acid levels in the rat anterior pituitary gland. Molecular Endocrinology, 2, No. 9, 775-784.
Moore, R.J., Gazak, J.M., Wilson, J.D. (1979) Regulation of cytoplasmic dihydrotestosterone binding in dog prostate by 17.beta.-estradiol. J. Clin. Invest., 63, 351-357.
Brooks, J.R., Baptista, E.M., Berman, C., Ham, E.A., Hichens, M., Johnston, D. B.R., Primka, R.L

Affiliated with

Also associated with

Rating

Androgen derivatives for use in the inhibition of sex steroid ac does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Androgen derivatives for use in the inhibition of sex steroid ac, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Androgen derivatives for use in the inhibition of sex steroid ac will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1250015